Title:
METHOD FOR PREDICTING RESPONSE TO VEGF TARGETED THERAPEUTICS
Document Type and Number:
WIPO Patent Application WO/2015/157655
Kind Code:
A3
Abstract:
The presently disclosed subject matter involves methods of predicting response in a subject to treatment for a disease with a VEGF targeted therapeutic, and for evaluating and/or monitoring treatment for a disease involving use of a VEGF targeted therapeutic in a subject. Such methods involve determining a level of ANGPTL4 expression in a biological sample from the subject; and comparing the level of ANGPTL4 expression in the sample with a reference, wherein the subject is predicted to be a likely responder or non-responder based on the ANGPTL4 expression in the sample relative to the reference. Administering a VEGF targeted therapeutic to the subject is initiated or continued when the subject is predicted to be a likely responder.
Inventors:
PFEFFER LAWRENCE M (US)
GARNER JO MEAGAN (US)
GARNER JO MEAGAN (US)
Application Number:
PCT/US2015/025341
Publication Date:
May 12, 2016
Filing Date:
April 10, 2015
Export Citation:
Assignee:
UNIV TENNESSEE RES FOUNDATION (US)
International Classes:
C12Q1/68; C07K16/26; G01N33/53
Domestic Patent References:
| WO2013022406A1 | 2013-02-14 |
Foreign References:
| US20100092485A1 | 2010-04-15 |
Other References:
ZHANG, H ET AL.: "Evaluation Of TGF-Beta, XP04, eIF5A2 And ANGPTL4 As Biomarkers In HCC.", EXP THER MED., vol. 5, no. 1, January 2013 (2013-01-01), pages 119 - 127, XP055279186
"RAYBIO HUMAN ANGPTL4 ELISA KIT.", USER MANUAL, 12 March 2014 (2014-03-12), pages 3, Retrieved from the Internet [retrieved on 20150702]
ZHANG, L ET AL.: "Resistance Of Renal Cell Carcinoma To Sorafenib Is Mediated By Potentially Reversible Gene Expression.", PLOS ONE., vol. 6, no. 4, 29 April 2011 (2011-04-29), pages 3, XP055279191
KUMARA, HMCS ET AL.: "Plasma Levels Of Angiopoietin-Like Protein 4 (ANGPTL4) Are Significantly Lower Preoperatively In Colorectal Cancer Patients Than In Cancer-Free Patients And Are Further Decreased During The First Month After Minimally Invasive Colorectal Resection.", SURG ENDOSC., vol. 26, no. 10, October 2012 (2012-10-01), pages 2751 - 2757, XP055279205
YI, J ET AL.: "Clinical Significance Of Angiopoietin-Like Protein 4 Expression In Tissue And Serum Of Esophageal Squamous Cell Carcinoma Patients.", MED ONCOL., vol. 30, no. 3, 8 August 2013 (2013-08-08), pages 3, XP055279297
HU , Z ET AL.: "A Compact VEGF Signature Associated With Distant Metastases And Poor Outcomes.", BMC MED., vol. 7, no. 9, 16 March 2009 (2009-03-16), pages 1 - 14, XP021051403
ABUBAKR, Y ET AL.: "The Role Of The Therapeutic Promise Of Targeted Angiogenesis Inhibitor In Management Of Metastatic Colorectal Cancer.", CANCER THERAPY., vol. 9, 3 October 2013 (2013-10-03), pages 55 - 64, XP055279300, Retrieved from the Internet [retrieved on 20150704]
ABD-ALLAH, GM ET AL.: "ANGPTL4 As Biomarker In Early Detection Of Cardiovascular Complications In Diabetic Patients.", INDIAN JOURNAL OF APPLIED RESEARCH., vol. 3, no. 4, April 2013 (2013-04-01), pages 16 - 19, XP055279305, Retrieved from the Internet> [retrieved on 20150704]
"RAYBIO HUMAN ANGPTL4 ELISA KIT.", USER MANUAL, 12 March 2014 (2014-03-12), pages 3, Retrieved from the Internet
ZHANG, L ET AL.: "Resistance Of Renal Cell Carcinoma To Sorafenib Is Mediated By Potentially Reversible Gene Expression.", PLOS ONE., vol. 6, no. 4, 29 April 2011 (2011-04-29), pages 3, XP055279191
KUMARA, HMCS ET AL.: "Plasma Levels Of Angiopoietin-Like Protein 4 (ANGPTL4) Are Significantly Lower Preoperatively In Colorectal Cancer Patients Than In Cancer-Free Patients And Are Further Decreased During The First Month After Minimally Invasive Colorectal Resection.", SURG ENDOSC., vol. 26, no. 10, October 2012 (2012-10-01), pages 2751 - 2757, XP055279205
YI, J ET AL.: "Clinical Significance Of Angiopoietin-Like Protein 4 Expression In Tissue And Serum Of Esophageal Squamous Cell Carcinoma Patients.", MED ONCOL., vol. 30, no. 3, 8 August 2013 (2013-08-08), pages 3, XP055279297
HU , Z ET AL.: "A Compact VEGF Signature Associated With Distant Metastases And Poor Outcomes.", BMC MED., vol. 7, no. 9, 16 March 2009 (2009-03-16), pages 1 - 14, XP021051403
ABUBAKR, Y ET AL.: "The Role Of The Therapeutic Promise Of Targeted Angiogenesis Inhibitor In Management Of Metastatic Colorectal Cancer.", CANCER THERAPY., vol. 9, 3 October 2013 (2013-10-03), pages 55 - 64, XP055279300, Retrieved from the Internet
ABD-ALLAH, GM ET AL.: "ANGPTL4 As Biomarker In Early Detection Of Cardiovascular Complications In Diabetic Patients.", INDIAN JOURNAL OF APPLIED RESEARCH., vol. 3, no. 4, April 2013 (2013-04-01), pages 16 - 19, XP055279305, Retrieved from the Internet
Attorney, Agent or Firm:
DING, Cong et al. (401 Commerce StreetNashville, Tennessee, US)
Download PDF:
Previous Patent: USER INTERFACE FOR VIEWING EVENT DATA
Next Patent: ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME
Next Patent: ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME